WW INTERNATIONAL, INC. Q3 FY2024 earnings call

Management Statement and Operational Highlights:

• Portfolio Advantage: WeightWatchers has a full spectrum weight management platform, actively focused on making it easier for members to move across program components.
• Scientific Advantage: Decades of R&D investment, with over 175 published clinical papers, and evidence showing behavioral programs are 3.5x more effective than standard nutritional guidance alone.
• Community Advantage: A highly motivated community with 60 million+ members supported by coaches, clinicians, etc., and a dynamic online community via the app.
• Brand Revitalization: Plans to refresh the brand, clarifying and unifying marketing messaging, especially in the clinical space.
• Clinical Business: Added compounded semaglutide to address drug shortages, saw improved clinic member retention to 7.5 months from 6.5 months, but competition drives high customer acquisition costs.
• Digital Member Journey: Focus on simplifying and integrating the digital experience to better serve members across all solutions.
• B2B Opportunities: Emerging clinical solutions create opportunities for employers and payers, with WeightWatchers' program offering a robust ROI.

Segment Performance:

• Subscription revenues totaled $191 million, down 6% year-over-year. Clinical subscription revenues contributed $9 million, with 78,000 clinical subscribers at the end of Q3, representing a 71% year-over-year growth.
• Other revenue was $2 million, down $10 million year-on-year due to the discontinuation of the low margin consumer products business.
• Adjusted gross margin was a record high of 69.1%, up from 66.2% in the prior year, driven by cost reduction actions and discontinuation of lower margin consumer products.
• Marketing expenses were $44 million, down 8% year-over-year.
• Adjusted G&A was $53 million, down 7% versus prior year.
• Adjusted operating income in Q3 was $36 million, with an operating margin of 18.5%, a year-over-year increase of almost 150 basis points.

Guidance:

• Reiterating full-year guidance for 2024: end-of-period subscribers at least 3.1 million, revenue at least $770 million, adjusted operating income at least $100 million, adjusted EBITDAS at least $150 million (excluding non-cash impairments and former CEO separation costs).
• Cash outlays for 2024 restructuring plan expected to be ~$30 million, with ~$5 million remaining in Q4.
• Full-year interest expense expected between $105 million and $110 million, up ~10%-15% year-over-year.
• Expected income tax expense up to $10 million, with a cash tax net of refunds of ~$20 million.
• Confident in liquidity with ~$57 million cash and undrawn revolver access of $61 million, and plans to invest in the business in 2025 to drive growth.

Risks:

• Competition: High customer acquisition costs driven by competition in the clinical space.
• Medication Shortages: Impact on clinic member access and business results.
• Insurance Coverage: Prohibitive for most clinic members, leading to churn.
• Foreign Currency: Negative impact on intercompany transactions reflected in other expenses.

Question and Answer: Q: Thoughts on what has worked early in the compounding launch across conversion, retention and marketing, and LTV to CAC?

A: Positive impact on sign ups and CAC immediately after compounding launch, driven by availability of supply and improved member experience. However, compounding is expected to have minimal impact on 2024 overall business results.

Q: Key priorities to drive reacceleration in core clinical ahead of peak season?

A: Focus on raising awareness of the breadth and strength of the offering, highlighting the full spectrum of WeightWatchers solutions, and leveraging the brand refresh and core strengths.

Q: Retention on clinical side, reasons for churn, and long-term expectations?

A: Cost and access are major factors in clinical churn. Longer term, emphasis on pairing clinical solutions with nutritional programs to keep members engaged with the brand.

Q: How much of $80 million cost cut savings will be reinvested and impact on bottom line?

A: Investment needed in the business for growth in 2025, with no 2025 guidance provided yet. The $100 million cost action includes investment, and full run rate savings expected by end of 2025.

Q: Confidence in employers offering more weight loss solutions and WeightWatchers' positioning?

A: Confident employers will need to offer weight loss solutions due to health benefits, and WeightWatchers is well-positioned with its full spectrum offering. B2B growth expected to be gradual but bullish on the opportunity.